Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
pD8fg7ew7nu6RC5h
